
Feature|Articles|August 17, 2026
Competing Vaccine Schedules Leave Pharmacists Navigating Confusion
Author(s)Ashley Gallagher, MA
A year of ACIP turnover, schedule changes, and lawsuits has fractured US vaccine guidance—and tied pharmacists' scope and billing to a moving target.
Advertisement
Advertisement
For more than 60 years, the Advisory Committee on Immunization Practice (ACIP), a committee of scientific and health experts, has driven federal vaccine recommendations later adopted by the CDC.¹ Since United States Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr was sworn in on February 13, 2025, that process has been upended through committee turnover, unilateral recommendation changes, ongoing litigation, and, most recently, competing vaccine schedules from federal agencies and nonfederal medical societies alike.
Related to this article

High-income countries gained the most economic value from COVID-19 vaccines but low-income countries got the most per-person vaccinations relative to GDP.

The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.

From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.

As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.

Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.

Owners believe clean plan-to-patient matching before January 1 is one of the simplest ways to protect cash flow in 2027.

The PAHO confirmed the loss after more than 12 months of continuous transmission, putting renewed focus on pharmacists' role in closing vaccination gaps.
Advertisement
Advertisement

